The US Food and Drug Administration commissioner nominee may have unintentionally got on the wrong side of some of his future colleagues with a seemingly benign comment about biosimilars and transparency.
During his 20 November confirmation hearing with the Senate Health, Education, Labor and Pensions Committee, Hahn was asked about his views on the FDA's role in preventing patent gaming. Sen....